> Diabetes Research > Once-a-week shot effective in Glucose Control

Once-a-week shot effective in Glucose Control

A newer and longer-acting form of the diabetes drug exenatide (Byetta) taken once a week did better at controlling blood glucose levels compared to its standard formula, according to a new study published recently in the journal, The Lancet.

Dr. Daniel J. Drucker and his colleagues from the Mount Sinai Hospital in Toronto, Canada, compared the two injectable formulations in 265 type 2 diabetics. The doses of the long-acting and standard forms were 2 milligrams and 10 micrograms, respectively.

Results showed that at 30-week follow-up, patients who received the longer-acting form had better glucose control than those who took the regular form of the drug. Also, 77 percent of those who took the longer-acting dose achieved their goal, compared to the 61 percent of patients who took the older formula. These benefits were achieved without increasing the risk of excessively low blood sugar or compromising weight loss.

According to Dr. Drucker and his team, the new exenatide “offers a promising treatment option for the management of type 2 diabetes.”

“When the once-a-week formulation becomes available, after confirmation and extension of today’s positive results, this new strategy might substantially change the management of type 2 diabetes,” said Dr. Andre Scheen from the University of Belgium, in another related editorial.

Related terms:

Related Posts:

» Tags: , , , , , ,

Related terms:

Leave a Reply

Your email address will not be published. Required fields are marked *